IP Library › Granted Patent US 9,314,430
Granted Patent B2
US 9,314,430 · App. 13/704,760 · Granted Apr 19, 2016

Floating gastric retentive dosage form

Inventors: Pascal Grenier (Kappelen, FR); Alain Nhamias (Bartenheim, FR); Guy Vergnault (Kembes, FR)
Assignee: Jagotec AG
A61K9/0065A61K9/4808A61K31/05A61K31/4045
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,314,430
App. No.
13/704,760
Granted
Apr 19, 2016
Kind
B2
Abstract

An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in. gastric fluid, wherein the dosage form is weight biased such that. one end is heavier than the ether end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the: fluid with its heavier end pointing: generally; downwards and into the fluid.

Claims (15)

1. An elongate dosage form of cylindrical shape in the form of a hollow capsule which is impermeable to gastric fluid and having a fill volume inside containing a weighting agent which is retained at one end of the fill volume, the dosage form being buoyant and self-orientating in an aqueous fluid such that it floats in the aqueous fluid with its long axis perpendicular to the surface of the aqueous fluid.

2. A dosage form according to claim 1 that has a length of at least 12 mm along its longest length.

3. A dosage form according to claim 1 wherein the weighting agent is in the form of a tablet.

4. A dosage form according to claim 1 wherein the weighting agent comprises an ingredient selected from the group consisting of barium sulphate, dibasic calcium phosphate, iron oxide, iron, titanium dioxide, calcium carbonate having a density of 1.3 or greater and calcium sulphate.

5. A dosage form according to claim 1 wherein a second capsule, smaller than the hollow capsule is disposed within the fill volume of the hollow capsule, the dimensions of the second capsule being such as to leave a space in the fill volume of the hollow capsule to receive the weighting agent and retain it at one end of the hollow capsule.

6. The dosage form of claim 5 , wherein the second capsule is hollow.

7. A dosage form according to claim 1 wherein the weighting agent is retained within the hollow capsule at one end thereof by means of a plug of waxy material that is formed around the weighting agent.

8. A dosage form according to claim 7 wherein the waxy material is macrogol or natural or semi synthetic lipidic waxes.

9. A dosage form according to claim 7 wherein the waxy material has a melting point above 37° C.

10. A dosage form according to claim 1 wherein the dosage form is coated with a coating material comprising a drug substance.

11. The dosage form of claim 1 , wherein the weight of the weighting agent ranges from 10 up to 500 mg.

12. The dosage form of claim 1 , wherein (1) the dosage form comprises a coating applied to the dosage form, the coating selected from (i) an enteric-coating, or (ii) a partly or wholly insoluble coating.

13. The dosage form of claim 1 , wherein the weight of the weighting agent ranges from 10 to 400 mg.

14. The dosage form of claim 1 , wherein the weight of the weighting agent ranges from 100 and 350 mg.

15. The dosage form of claim 1 , wherein the weight of the weighting agent ranges from 50 to 250 mg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2013
From: GRENIER, PASCAL; NHAMIAS, ALAIN; VERGNAULT, GUY
To: JAGOTEC AG
Reel/Frame 029642/0259 →
Priority Claims (2)
GB 1011271.2 · Jul 5, 2010 · national
GB 1018917.3 · Nov 9, 2010 · national
Continuity (1)
Related Publication 20130108695A1 · May 2, 2013